SWOG

SWOG -- nCartes Leap Day Webinar Conveys a Leap Forward

Retrieved on: 
Thursday, March 14, 2024
Statistics, Q&A, SWOG, Research, Hospital, Biostatistics, Leap Day, Doctor of Philosophy, EDC, EHR

SEATTLE and FREMONT, Calif., March 14, 2024 /PRNewswire-PRWeb/ -- The SWOG-nCartes Electronic Health Record (EHR)-to-Electronic Data Capture (EDC) Collaboration held a webinar on February 29th to educate SWOG clinical research sites on the SWOG-nCartes opportunity.

Key Points: 
  • I am excited about the opportunities to achieve effort savings at the institutions and to further our mission of ensuring the highest quality data for SWOG trials.
  • Using nCartes, clinical research professionals review data from the EHR that are automatically available for input into trial forms within the nCartes system and are then directly passed to the SWOG EDC.
  • The well attended Leap Day virtual event featured a Q&A panel that included staff from sites currently using the SWOG-nCartes system.
  • The SWOG SDMC, jointly located at the Fred Hutch Cancer Center and Cancer Research And Biostatistics in Seattle, recently completed an in-depth analysis of nCartes use across several SWOG sites and trials.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Expansive Portfolio of Hematology/Oncology Data at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Tuesday, November 28, 2023
Acute promyelocytic leukemia, ATRA, NCI-designated Cancer Center, Research, Safety, RWJBarnabas Health, Toxicity, Progression-free survival, National Cancer Institute, Bone marrow, Ageing, ASH, Consortium, EFS, Clinical trial, Leukemia, Holism, Patient, PFS, Probability, APL, SWOG, Hodgkin lymphoma, Exposition, Multiple myeloma, CHL, Prognosis, Abstract, Diagnosis, Cancer, Death, Partnership, Arsenic trioxide, Society, Cooper University Hospital, Health, Lymphoma, Pharmaceutical industry, Medical device, MD

NEW BRUNSWICK, N.J., Nov. 28, 2023 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present an extensive array of hematology/oncology data from their clinical research program at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in San Diego, California (and virtually) from December 9-12, 2023. A total of 36 abstracts have been accepted, comprising clinical data and analyses that advance the understanding, treatment, and prognosis of blood cancers such as lymphoma, leukemia, and myeloma. Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • "As the leading cancer program in the state, our commitment to advancing oncology care is unwavering.
  • The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), event-free survival (EFS), and safety.
  • The full list of presentations at this year's ASH Annual Meeting and Exposition follows:

Agendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan's Dr. Erin Cobain

Retrieved on: 
Tuesday, October 31, 2023
Principal, MP2, Breast, NCI, MP, HER2, MD, PCR, SWOG, Doctor of Philosophy, National Cancer Institute, Clinical trial, Neoplasm, NSC, Breast cancer, Recurrence, Immunotherapy, University, HR, Gene, Wright Axcess-Ultralow, Woman, Cancer, University of Michigan, Patient, Gene expression profiling, Birth control, Pharmaceutical industry, Health, MammaPrint

IRVINE, Calif. and AMSTERDAM, Oct. 31, 2023 /PRNewswire/ -- Agendia, Inc., a global leader in innovative genomic technology and diagnostic tests, is collaborating with National Cancer Institute (NCI), part of the National institutes of Health and SWOG Cancer Research Network, funded by NCI, for a new clinical trial that will test the effectiveness of neoadjuvant immunotherapy for high-risk HR+ breast cancer patients.

Key Points: 
  • SWOG S2206 will use MammaPrint® breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
  • This trial is sponsored by NCI and led by SWOG with participation of the National Clinical Trials Network (NCTN).
  • Dr. Erin Cobain, MD, University of Michigan, will be the Principal Investigator of S2206.
  • Also collaborating on the study is Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center, who serves as the SWOG Breast Cancer Committee Chair.

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Retrieved on: 
Thursday, October 26, 2023
Multiple myeloma, American Society of Clinical Oncology, American Society of Hematology, Clinical Cancer Research, Coronavirus Scientific Advisory Board, Albert Einstein College of Medicine, MD, Harry Oppenheimer Fellowship Award, Stanford Department of Electrical Engineering, SWOG, Stanford University Medical Center, Society, Memorial, International Society, Patient, ASCO, Nursing, Amyloidosis, Hematology, Hannover Medical School

LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.
  • Dr. Liedtke brings decades of experience in hematology/oncology clinical trials, clinical trial design, and thought leadership to Nexcella.
  • “We need more effective treatments to improve the outcomes for patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma,” said Dr. Liedtke.
  • We are excited to be working with Dr. Liedtke.”
    Dr. Liedtke is the Stanford University Medicine Cancer Center Program Lead, Hematology; Co-Director, Stanford Amyloid Center; Medical Director, Stanford Adolescent and Young Adult Program; and Member Leukemia Committee, Southwest Oncology Group.

Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Retrieved on: 
Thursday, October 26, 2023
Multiple myeloma, American Society of Clinical Oncology, American Society of Hematology, Clinical Cancer Research, MD–PhD, Coronavirus Scientific Advisory Board, Albert Einstein College of Medicine, MD, Harry Oppenheimer Fellowship Award, Stanford Department of Electrical Engineering, SWOG, Stanford University Medical Center, Society, Memorial, International Society, Patient, ASCO, Nursing, Amyloidosis, Hematology, Hannover Medical School

LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined the Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined the Nexcella Scientific Advisory Board.
  • Dr. Liedtke brings decades of experience in hematology/oncology clinical trials, clinical trial design, and thought leadership to Nexcella.
  • We are excited to be working with Dr. Liedtke.”
    Dr. Liedtke is the Stanford University Medicine Cancer Center Program Lead, Hematology; Co-Director, Stanford Amyloid Center; Medical Director, Stanford Adolescent and Young Adult Program; and Member Leukemia Committee, Southwest Oncology Group.
  • Dr. Liedtke completed her fellowship at Stanford University Medical Center and Memorial Sloan-Kettering Cancer Center, residency at the Albert Einstein College of Medicine, and received her medical degree from Medizinische Hochschule Hannover.

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Retrieved on: 
Tuesday, October 10, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, NYSE, Abstract, Breast cancer, Brentuximab vedotin, INT, Trastuzumab, RCC, Survival, Endometrial cancer, PEM, NRG, ESMO, Merck & Co., Webcast, Belzutifan, European Society for Medical Oncology, ADC, Research, TUC, KRAS, Lung cancer, RAS, AstraZeneca, EC, Adenocarcinoma, Head, TNBC, MRK, Pembrolizumab, Everolimus, CRC, Cancer, Olaparib, EFS, Quality of life (healthcare), SWOG, Congress, LBA32, LBA21, PBO, Chemoradiotherapy, CP, Safety, MBC, Patient, Pharmaceutical industry, Birth control, Medical imaging, Animal feed, Vaccine, Tras, Merck, NSCLC, Eisai

The event will take place virtually and will be accessible via webcast.

Key Points: 
  • The event will take place virtually and will be accessible via webcast.
  • Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC.
  • Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma from SWOG S1801.
  • mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response.

Myeloma Support Group Leader Jack Aiello and Global Finance & Strategy Leader Sanjay Singh Elected to International Myeloma Foundation Board of Directors

Retrieved on: 
Thursday, July 27, 2023
Survivor, QVC, Education, Marketing, Multiple myeloma, Family medicine, UGI Corporation, Public policy, Research, Business plan, Procter, Kellogg's, Aiello, Intel, Procter & Gamble, International Myeloma Foundation, Patient, Analysis, CFO, Knowledge, Growth, P&G, Qurate Retail Group, Caregiver, SVP, NCI, SWOG, Grid Systems, IMF, Management, Nursing, Sanjay, MD

LOS ANGELES, July 27, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed two of its newest Board Members: Myeloma Support Group Leader and 28-year myeloma survivor Jack Aiello, and Global Finance and Strategy Leader and 2-year myeloma survivor Sanjay Singh.

Key Points: 
  • LOS ANGELES, July 27, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed two of its newest Board Members: Myeloma Support Group Leader and 28-year myeloma survivor Jack Aiello, and Global Finance and Strategy Leader and 2-year myeloma survivor Sanjay Singh.
  • “Jack’s prominent standing and respect within the myeloma patient circle makes his presence on the IMF Board of Directors even more significant.
  • As a patient member of the SWOG NCI cooperative group Myeloma Committee, Jack helped design myeloma clinical trials which are meaningful and useful for patients.
  • Jack has led the San Francisco Bay Area Support Group Multiple Myeloma for 20 years, and always stresses [the importance of] education and self-advocacy.

The Caris Precision Oncology Alliance Welcomes SWOG Cancer Research Network

Retrieved on: 
Wednesday, June 14, 2023
Database, National Cancer Institute, FACP, Cancer, Intelligence, MBA, Research, Biomarker, Publication, POA, Patient, Machine learning, NCI, SWOG, Medical imaging

IRVING, Texas, June 14, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that SWOG Cancer Research Network has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. POA members are uniquely positioned to leverage Caris' highly sophisticated AI bioinformatics and machine learning capabilities across the company's massive clinico-genomic database to enable innovative research to improve clinical outcomes for cancer patients.

Key Points: 
  • IRVING, Texas, June 14, 2023 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that SWOG Cancer Research Network has joined the Caris Precision Oncology Alliance™ (POA).
  • SWOG Cancer Research Network is a global oncology research community of over 18,000 members in 45 states and 10 countries who design and conduct publicly funded clinical trials.
  • "SWOG Cancer Research Network is excited to join the Caris Precision Oncology Alliance," said Charles D. Blanke, M.D., group chair of the SWOG Cancer Research Network.
  • Welcoming SWOG Cancer Research Network to the growing Caris POA network is a big milestone destined to help all patients diagnosed with cancer," said Chadi Nabhan , M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance.

SWOG-nCartes Collaboration Presented at the Spring 2023 SWOG Hybrid Group Meeting

Retrieved on: 
Wednesday, May 31, 2023
EHD, Research, Doctor of Philosophy, UC, SAN, Liverpool Data Research Associates, CCRP, SWOG, EDC, Pharmaceutical industry

SAN FRANCISCO, May 31, 2023 /PRNewswire/ -- The SWOG-nCartes EHR-to-EDC collaboration between nCoup and the SWOG Cancer Research Network was showcased at the Spring 2023 SWOG Hybrid Group Meeting earlier this month in San Francisco.

Key Points: 
  • SAN FRANCISCO, May 31, 2023 /PRNewswire/ -- The SWOG-nCartes EHR-to-EDC collaboration between nCoup and the SWOG Cancer Research Network was showcased at the Spring 2023 SWOG Hybrid Group Meeting earlier this month in San Francisco.
  • Having completed a successful SWOG-nCartes pilot, nCartes is now live on several SWOG trials with more sites joining at an accelerating pace.
  • In addition, following the pilot success, SWOG expanded the collaboration to support ten clinical trials.
  • "SWOG has been an exceptional partner working with nCoup to unleash the value of nCartes for SWOG cancer research sites," says nCoup CEO John McIlwain.

OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

Retrieved on: 
Tuesday, May 16, 2023
Apoptosis, Communication, US Foods, Electroporation, Disease, SWOG, IST, Cancer, Type, PCR, Melanoma, Patient, Collection, SAN, PMR, Immune system, Clutch (eggs), EFS, Merck, FDA, Pembrolizumab, Food, Nivolumab, Pharmaceutical industry

The meeting with the FDA represents an important next step on the Company's path to pursue clinical development of TAVO™-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting.

Key Points: 
  • The meeting with the FDA represents an important next step on the Company's path to pursue clinical development of TAVO™-EP in combination with anti-PD-1 therapy in the neoadjuvant melanoma setting.
  • In the randomized stage, neoadjuvant treatment with TAVO™-EP in combination with pembrolizumab will be compared to pembrolizumab alone.
  • The rationale for the proposed trial is an evolving standard of care in neoadjuvant melanoma treatment.
  • The Company appreciates the productive meeting with the FDA and the agency's feedback on the trial design and potential strategies for future registrational paths.